Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19
How to Cite
OrthoEvidence. Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19. ACE Report. 2021;11(1):3. Available from: https://myorthoevidene.com/AceReport/Report/13251
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialLancet. 2021 Feb 13;397(10274): 605-612.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Of the 9433 patients participating in the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, 7763 were randomized to receive azithromycin plus standard care (n=2582), or standard care alone (n=5181; 837 eventually crossed over to receive azithromycin or tocilizumab but were still included in the analysis). The primary outcome of interest was all-cause mortality at 28 days. Secondary outco...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE